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Abstract
Objective: The objective of this selective EBM review is to determine whether or not “Are
Monoclonal Anti-CGRP Antibodies Effective in the Treatment of Adults with Migraines?”
Study Design: A review of three randomized control trials (RTCs) written in English, published
in 2014, 2015, and 2016.
Data Sources: Each study was published in a peer-reviewed journals found via the PubMed
database. These studies measured the effectiveness of monoclonal anti-CGRP antibodies in
relieving migraines in adults.
Outcomes Measured: The outcomes measured in these trials were by how much monoclonal
anti-CGRP antibodies lead to a decrease from baseline in the frequency of migraine hours or
days, as compared to a placebo. Migraine days were recorded by patients using an electronic
headache diary, and defined by the International Classification of Headache Disorders II.
Results: Bigal (2016) and co-authors demonstrated significant improvement in number of
headache hours at the end of the first week of treatment using 900-mg of TEV-48125 as
compared to the placebo group. Bigal (2015) and co-authors found a higher decrease in number
of headache days during weeks 9-12 in the group receiving 225 mg of TEV-48125 over the
group receiving the placebo. Dodick et al also demonstrated a higher decrease in number of
headache days by weeks 5-8 in the group receiving ALD403 compared to the placebo group.
Conclusion: The studies reviewed in this paper demonstrate that monoclonal anti-CGRP
antibodies are an effective treatment for adults with migraines. Although this is a fairly novel
therapy with further research still underway, this new drug class is a hopeful therapy option for
adults suffering from migraine headaches.
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INTRODUCTION
Migraine headaches are a common and debilitating disorder. They are characterized as an
acute, primary headache and can be accompanied by nausea, vomiting, photophobia, and
phonophobia.2 Migraines are described as a severe, throbbing pain on one side of the head, but
they can also be bilateral.9 On average, attacks last from 4 to 72 hours and can result in an
accumulation of a large amount of missed days of work, school, activities, and productivity
throughout a persons lifetime.9 It should be noted that a migraine is not just a bad headache, but a
neurological disorder accompanied by incapacitating symptoms.9 Over 70% of those who suffer
from migraines reported being disabled due to their condition, while 30% reported severe
disability and reduction in quality of life.7
Migraine is the 3rd most common illness in the world with 18% of American women and
6% of American men suffering.9 Over 4 million adults experience migraines daily.9 Due to the
staggering number of Americans suffering from migraines, healthcare costs and lost productivity
associated with migraines add up to approximately $36 billion annually in the US.9 It is believed
that about 1.2 million healthcare visits each year in the US are due to migraines.9 Classically,
General Practitioners have been the most common avenue for which individuals experiencing
migraines seek treatment and care.7 The large number of individuals suffering from migraines in
conjunction with the rising number of midlevel providers means that Physician Assistants in a
variety of specialties can expect to come in contact with, and often treat, patients afflicted by this
condition.
The exact mechanism of migraine headaches is not proven, but it is believed that they are
due to neurovascular dysfunction. This dysfunction happens when the dilation of blood vessels
innervating the trigeminal nerve and release of neuropeptides cause peripheral sensitization and

Johnston, Migraines & Monoclonal Anti-CGRP Antibodies 2	
  
headache.5 Migraines are associated with a complex pattern of inheritance, and an autosomal
dominate inheritance pattern is commonly seen.5 They typically begin to affect individuals in
their teens or twenties, and become less frequent in the forties and fifties.10
Unfortunately, there is no proven cure for migraine headaches, and treatment is based on
abortive and preventative measures.10 As with many other medical conditions, the treatment of
migraines is often a trial and error process to determine what works best for each patient.
Patients may first wish to pursue nonpharmalogical options, such as acupuncture, massage, and
rest and relaxation.7 Simple analgesics like acetaminophen, Excedrin, and other NSAIDS are
commonly used to treat migraines.3 Triptans and Ergotamines are a mainstay of treatment for
more moderate to severe attacks.3Antiemetics can be used to control symptoms.3 Daily use of
propranolol, topiramate, and verapamil may be considered for prevention in individuals suffering
from frequent migraine attacks.10
Although there are several treatment options for migraines, many patients are still unable
to find relief, whether it be due to medication side effects, or their lack of efficacy.7 Recently,
monoclonal antibodies against the calcitonin gene-related peptide (CGRP) have been evaluated
for their effectiveness in the preventative treatment of adults with migraine.2 CGRP is a
neuropeptide widely distributed throughout the central and peripheral nervous system, and is
associated with pain transmission and vasodilation.2 During a migraine attack, serum levels of
CGRP rise.2 Antagonism of this pathway through monoclonal anti-CGRP antibodies is a new
and hopeful method in the prevention and acute treatment of migraines.2 This paper evaluates
three randomized control trials comparing the efficacy of monoclonal anti-CGRP antibodies in
the treatment of adults with migraines.
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OBJECTIVE
The objective of this selective EBM review is to determine whether or not monoclonal
anti-CGRP antibodies are effective in the treatment of adults with migraines.
METHODS
This systematic review utilized three randomized control trials (RTCs), all of which
focused on adults greater than 18 years old diagnosed with migraine headaches, as per the
International Classification of Headache Disorders. All trials used monoclonal anti-CGRP
antibodies as the intervention, comparing it to a visually matched placebo. Outcomes measured
included change from baseline in the frequency of headache hours and days compared to
placebo. Each of the studies were randomized, double blind, placebo-controlled studies.
An extensive search of the PubMed database was completed by the author between
November 2016 and February 2017 using the key words “migraine” and “monoclonal antiCGRP antibodies”. Articles were published in English, and in peer-reviewed journals. They were
selected based on their relevance to the clinical question, and if they included patient oriented
outcomes. Inclusion criteria were randomized, double blind trials published after 2001, that
compared monoclonal anti-CGRP antibodies to a placebo in patients diagnosed with migraine
headaches. Exclusion criteria included patients under the age of 18, patients with history of any
other type of headache not classified as a migraine, or if they had tried 3 or more preventative
drugs without efficacy. Summary of statistics reported or used include change from baseline, pvalue, ARR, and NNT. Table 1 displays the demographics and characteristics of these three
articles.
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D. Table 1- Demographics and Characteristics of Included Studies
Study

Type

# Pts

Age
(years)
18-65

1

Bigal
(2016)

Double 261
Blind
RTC

Bigal2
(2015)

Double 297
Blind
RTC

18-65

Dodick4 Double 174
(2014)
Blind
RTC

18-55

Inclusion
Criteria

Exclusion Criteria

W/D

Interventions

Patients
18-55 with
history of
chronic
migraine
and
compliant
with
electronic
headache
diary
Patients 18
and older
who had
migraine
headaches
for 8-14
days per
month and
showed
compliance
with
electronic
headache
diary
Patients
18-55 with
more than
12 months
of
migraines,
diagnosed
before age
50, who
were
compliant
with the
electronic
headache
diary for a
28 day trial

Received
onabotulinumtoxin
A during the 6
months before
study entry and if 3
or more preventive
medications failed
because lack of
efficacy

39

A
subcutaneous
injection of
monoclonal
anti-CGRP
antibody
TEV-48125
900mg, at the
beginning of
the study

Patients with
chronic migraine,
those using opioids
or barbiturates for
more than 4 days
during the run in
phase, those who
tried 3 or more
preventative drugs
without efficacy

28

Subcutaneous
monoclonal
anti-CGRP
antibody,
TEV-48125
225 mg,
injected at the
beginning of
the treatment
cycle

Regular and
effective use of
preventative drugs
within 3 months,
received Botox A
within last 6
months, history of
Chronic tension
headache, hypnic
headache, new
daily persistent
headache, basilartype, sporadic or
familial hemiplegic
migraine

11

Subcutaneous
dose of
monoclonal
anti-CGRP
antibody
ALD403
1000mg,
injected at the
beginning of
the study
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OUTCOMES MEASURED
Outcomes were measured on the basis of patient reporting. Patients reported migraine
information daily, using an electronic headache diary. A migraine day is defined as any day with
migraine or probable migraine according to the International Classification of Headache
Disorders II. In Bigal (2016) et al1, the change from baseline in the number of headache days
during the first, second, and third weeks of treatment with monoclonal anti-CGRP antibodies,
specifically TEV-48125, was evaluated.1 This paper will focus on the change from baseline in
number of headache hours in week 1, using the 900-mg dose. The study by Bigal (2015) et al 2
measured the mean decrease from baseline in the number of days fulfilling migraine criteria
during the third treatment cycle, weeks 9-12, among other secondary endpoints not discussed in
this paper. This paper focuses on the mean change from baseline in migraine days during weeks
9-12 in those receiving 225 mg of TEV-48125 vs placebo. Dodick et al4 measured the change
from baseline in the frequency of migraine days in placebo vs ALD403 at various time points,
among other secondary endpoints.4 This paper focuses on mean change from baseline in number
of migraine days in placebo vs ALD403 during weeks 5-8.
RESULTS
Bigal (2016) et al1 included 261 men and women aged 18 to 65 in the trial. 39 patients
did not complete the study, for reasons including lack of efficacy, lost to follow-up, nonfatal
adverse events, protocol deviation, and withdrawal of consent. Patients were randomized to
receiving a 900-mg injection of monoclonal anti-CGRP TEV-48125, a 675/225-mg injection, or
a visually matched placebo, however this paper will focus on the results of the efficacy of the
900-mg injection compared to the placebo.1 The 900-mg arm group consisted of 85 individuals
receiving 4 active injections of 225 mg/1.5 mL once monthly.1 The placebo group consisted of
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89 individuals who received 4 placebo injections monthly.1 The mean decrease in number of
headache hours in the first week of treatment will be discussed in this paper. All patients in all
groups were diagnosed with migraines and could continue to use up to two standard migraine
preventive medications if they had been on a stable dose for at least 3 months before the onset of
the study.1 They had to show higher than an 80% compliance with an electronic headache diary
during a 28-day trial period to be eligible for the study.1 They were excluded if they had received
onabotulinumtoxinA 6 months before the onset of the study, or if 3 or more preventative
medications had already failed due to lack of efficacy, although the reasoning for this was not
stated.1 Patients were selected from 62 sites in the US, including headache centers, neurology
clinics, and primary care sites.1 Overall compliance for baseline and the first month post
treatment was 92%, but methods of this evaluation were not discussed in the article.1 All efficacy
variables were analyzed by the intent-to-treat principle. By the end of week 1, the LSM change
from baseline in number of headache hours for the placebo group was -2.85 (SD 2.21) as
compared to a larger decrease of -11.37 (SD 2.26) for 900-mg of TEV-48125.1 LSM difference
between the two was -8.52 (95% CI: -14.27, -2.87, p=0.003).1 The NNT to achieve a greater than
50% reduction from baseline in number of headache hours by the end of week one was 11.1%,
meaning that for every 11 patients treated with monoclonal anti-CGRP antibodies over placebo,
one additional patient will experience a reduction in migraine hours.1 Specific adverse events of
the studied treatment were not discussed. These results can be seen in Table 2.
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Table 2: Analysis of data comparing reduction of headache hours after week 1 using
900-mg TEV-48125 and placebo reported by Bigal et al.
LSM from
baseline,
placebo
-2.85 (2.21)

LSM from
baseline,
TEV-48125
-11.37 (2.26)

LSM
difference
-8.52

95%
Confidence
Interval
-14.27, -2.87

ARR

% NNT

9

11

The 2015 Bigal et al2 study included 297 men and women ages 18 to 65 who had
migraine headaches 8-14 days per month. Patients were randomly assigned to groups, with 104
receiving a placebo, 95 received 225mg of TEV-48125, and 96 received 675 mg of TEV-48125.2
All were given subcutaneous injections once every 28 days for 3 months.2 Inclusion criteria is as
follows: patients with at least 8-14 headache days per month, may have used stable doses of one
migraine preventative drug for at least two months before screening, and may have used acute
migraine drugs up to 14 days a month.2 They had to demonstrate at least 80% compliance with
an electronic headache diary during this 28-day run in phase.2 Exclusion criteria is: patients
fulfilling criteria for chronic migraines, used opioids or barbiturates for more than 4 days during
the run-in phase, or had tried 3 or more preventative drugs without efficacy.2 Patients were
selected from 62 sites in the US, including headache centers, neurology clinics, and primary care
sites.2 28 withdrew from the treatment whether from lack of efficacy, lost to follow up, protocol
deviation, non-fatal adverse events, or withdrawal of consent.2 23% of patients in the placebo
group and 27% of patients in the 225 mg group reported treatment related adverse events, which
include minor injection site reactions and pain.2 Intention to treat analysis was used.2 This paper
will focus on the mean change from baseline in migraine days during weeks 9-12 in those
receiving 225 mg of TEV-48125 vs placebo.2 The least square mean change in number of
migraine-days in the third treatment cycle (weeks 9-12) relative to baseline was -3.46 migraine
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days (SD 5.40) in the placebo group vs a larger decrease of -6.27 migraine-days (5.38) in the 225
mg group.2 The LSM difference was -2.81 (95% CI:-4.07, -1.55, p<0.0001).2
NNT and NNH were not calculated because the study did not provide the number of
patients that achieved reduction in headache days.
Table 3: Analysis of data comparing LSM change from baseline in number of migraine
days using placebo or 225mg TEV-48125 at weeks 9-12 reported by Bigal (2015) et al
LSM change from baseline,

LSM change from baseline,

LSM difference placebo vs

placebo

900 mg TEV-48125

225mg

-3.46 (5.40)

-6.27 (5.38)

-2.81 (-4.07, -1.55)

p<0.0001, CI 95%
The 2014 study by Dodick et al4 included patients age 18-55 years suffering from
migraines. Specific location sites for patient selection were not discussed. Inclusion criteria is as
follows: patients with more than 12 months of migraine, diagnosed before age 50, frequency of
5-14 migraines per 28 day period in each of the 3 months before screening, and showed
compliance with electronic headache diary in 25 out of the 28 day run in period.4 During the 28day screening, patients had to have experienced at least 5 and up to 15 migraines to be included.4
Patients could use acute migraine drugs for 14 days or less per 28 day period in the 3 months
before and during the initial screening period.4 Exclusion criteria is: history of regular use of any
headache preventative drug with evidence of efficacy from a placebo-controlled trial within 3
months of the initial screening, received botulinum A toxin within 6 months before screening, or
had a history of any other type of headache.4 174 patients were randomly assigned to groups,
with 82 receiving the placebo, and 81 received an infusion of ALD403.4 11 of the assigned
individuals did not receive the allocated injection due to withdrawal of consent, ineligibility, or
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scheduling issues.4 Adverse events were experienced by 52% of patients in the placebo group
and 57% in the ALD403 group, including URI, UTI, fatigue, nausea, vomiting, and arthralgia.4
Intention to treat analysis was utilized. The study measured the mean change in migraine days
from baseline in patients receiving placebo vs ALD403 at different time points.4 This paper will
focus on mean change from baseline in weeks 5-8. The mean change in migraine days from
baseline between weeks 5-8 was -4.6 (3.6) for placebo as compared to a larger decrease of -5.6
(SD 3.0) for the ALD403 group.4 The difference is -1.0, (95% CI: -2.0, 0.1, p=0.0306).4
Table 4: Analysis of data comparing change from baseline in number of migraine days
during weeks 5-8 using placebo vs ALD403 reported by Dodick et al
Mean change from baseline,

Mean change from baseline,

Difference in mean change

placebo

ALD403

from baseline

-4.6 (3.6)

-5.6 (3.0)

-1.0 (-2.0, 0.1)

p=0.0306, CI 95%
During weeks 5-8, patients who showed at least a 50% response was 50% of placebo
patients (43/80), 75% of ALD403 patients (58/77), with the difference being 22% (95% CI: 7,
35).4 Using this information, the Relative Risk Reduction (RRR) of 0.3888, Absolute Risk
Reduction (ARR) of 0.21, and Number Needed to Treat (NNT) of 4.76 was calculated, meaning
that for every 5 patients treated with ALD403 over placebo, one additional patient will
experience reduction in migraine days than the placebo group.4
Table 5: Analyzation of data for 50% responders during weeks 5-8 in placebo vs ALD403
treatment, as reported by Dodick et al
CER (placebo)

EER (ALD403)

RRR

ARR

NNT

0.54

0.75

0.388888

0.21

4.76
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DISCUSSION
The three studies discussed in this review suggest that monoclonal anti-CGRP antibodies
are effective in the treatment and prevention of migraine headaches in adults. All studies showed
monoclonal anti-CGRP antibodies to be superior to the placebo in decreasing frequency of
migraine headaches. The statistical significance in all three studies was p<0.05, supporting
monoclonal anti-CGRP antibodies in the treatment of migraine headaches.
The review has multiple limitations that are worth mentioning. Firstly, two studies
included adults 18-65, while another focused on adults 18-55; however migraine headaches still
affect both young and the elderly. Another limitation to this review is that no studies had an
extensive follow up period to determine the efficacy of these treatments on a long-term basis. It
is believed that the intravenous administration in these studies could have contributed to a higher
rate of placebo response, as well as expectation in light of the novelty of the monoclonal antiCGRP drug class. Another point to note is that all studies observed the efficacy of monoclonal
anti-CGRP drugs on a scheduled, and not as needed or symptomatic basis.
The most significant aspect of this review to discuss is the novelty of this drug class.
Monoclonal anti-CGRP drugs are still in clinical trials, and have not yet been approved by the
FDA as a treatment for migraine headaches.6 Unfortunately, once this drug does become
available for public use, treatments are expected to begin at a cost of $8,000, and insurance
coverage is unclear.6 However, it is encouraging to note that all trials in progress as well as
completed, including the three mentioned in this review, have shown no major or concerning
side effects of this new drug class. The class will hopefully be on the market in early 2018.6
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CONCLUSION
Monoclonal anti-CGRP antibodies are effective in the treatment of adults with migraines.
The three randomized control trials discussed in this review showed improvement in outcomes
measured after the use of monoclonal anti-CGRP antibodies. Based on these results, monoclonal
anti-CGRP antibodies should be used as a new medication for the prevention and treatment of
migraine headaches in adults.
Despite this convincing evidence, further research should be done in order to determine if
long lasting relief can be achieved through the use of this treatment, potential long-term side
effects of the medication, and their effectiveness and safety in children, the elderly, and pregnant
women. Currently, there are four specific monoclonal anti-CGRP antibodies that are expected to
be on the market within the next year or sooner. These are Alder, Amgen, Lilly, and Teva.8 All
but one of these medications requires administration by a physician, which introduces a burden
to providers who will have to obtain approval for administration of the new drug.8 Further
research into more practical and independent administration methods for this migraine treatment
will be beneficial to both patients and providers alike. All studies in this review investigated the
effectiveness of monoclonal anti-CGRP antibodies in the treatment of migraines as compared to
a placebo, so there is little information regarding their efficacy in comparison to the standard
migraine treatments of today. However, there are currently several recently completed or
ongoing Phase 3 trials underway, which are expected to shed some light on the efficacy of this
treatment in comparison to the standard, treatment of choice, migraine medications.8 Although
the three studies discussed in this review answered the question that monoclonal anti-CGRP
antibodies are effective in the treatment of adults with migraines, there are still many questions
to be answered and much to be discovered on this new and promising treatment option.
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